These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27283966)

  • 1. A microscopic landscape of the invasive breast cancer genome.
    Ping Z; Xia Y; Shen T; Parekh V; Siegal GP; Eltoum IE; He J; Chen D; Deng M; Xi R; Shen D
    Sci Rep; 2016 Jun; 6():27545. PubMed ID: 27283966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.
    Gruel N; Benhamo V; Bhalshankar J; Popova T; Fréneaux P; Arnould L; Mariani O; Stern MH; Raynal V; Sastre-Garau X; Rouzier R; Delattre O; Vincent-Salomon A
    Breast Cancer Res; 2014 May; 16(3):R46. PubMed ID: 24887297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
    Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the Breast Ductal Carcinoma
    Hendry S; Pang JB; Byrne DJ; Lakhani SR; Cummings MC; Campbell IG; Mann GB; Gorringe KL; Fox SB
    Clin Cancer Res; 2017 Sep; 23(17):5210-5217. PubMed ID: 28611201
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
    Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
    J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
    O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
    Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
    Croessmann S; Wong HY; Zabransky DJ; Chu D; Rosen DM; Cidado J; Cochran RL; Dalton WB; Erlanger B; Cravero K; Button B; Kyker-Snowman K; Hurley PJ; Lauring J; Park BH
    Breast Cancer Res Treat; 2017 Apr; 162(3):451-464. PubMed ID: 28190247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
    Moon WK; Chen HH; Shin SU; Han W; Chang RF
    Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
    Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
    Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
    Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
    Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PIK3CA gene is mutated with high frequency in human breast cancers.
    Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
    Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
    Resteghini C; Perrone F; Miceli R; Bergamini C; Alfieri S; Orlandi E; Guzzo M; Granata R; Galbiati D; Cavalieri S; Locati L; Licitra L; Bossi P
    Tumori; 2018 Jun; 104(3):213-220. PubMed ID: 29714670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.